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Grenoble, France
Background: Endovascular radiofrequency obliteration has been used as an alternative to conventional vein-stripping
surgery for elimination of saphenous vein insufficiency. A clinical registry was established in 1998, and its mid-term
results have been reported previously. This study is to demonstrate the long-term treatment outcomes and to determine
the risk factors that affect treatment efficacy.
Methods:Data were collected in an ongoing multicenter, prospective registry. Patients were treated before October 2004.
Clinical and duplex ultrasound follow-up was performed 1 week, 6 months, 1 year, and yearly thereafter to 5 years.
Treatment efficacy and clinical improvement after the procedure were analyzed. Three types of anatomical failure were
identified. Logistic regression analysis was performed to determine the existence of any significant risk factors associated
with anatomical failure. Risk factors considered were age, gender, body mass index, vein diameter, and pullback speed.
The impact of anatomical failure on clinical symptoms and varicose vein recurrence was also analyzed.
Results: There were 1,006 patients (1,222 limbs) treated, their mean age was 47.4  12.1 years, and 78.1% were female.
Veins treated included 89.1% great saphenous vein above-knee segments, 1.2% great saphenous vein below-knee
segments, 4.1% great saphenous vein groin-to-ankle, 4.3% small saphenous veins, and 1.3% accessory saphenous veins.
Mean vein diameter was 7.5 mm, with a maximum of 24 mm. Vein occlusion rates were 87.1%, 88.2%, 83.5%, 84.9%, and
87.2%, and reflux-free rates were 88.2%, 88.2%, 88.0%, 86.6%, and 83.8% at each annual follow-up. Clinical symptom
improvement was seen in 70% to 80% of limbs with anatomical failures and in 85% to 94% of limbs with anatomical success
from 6months to 5 years after the radiofrequency obliteration. Logistic regression analysis showed that catheter pullback
speed (P < .0001) and body mass index (P < .0333) were risk factors for anatomical failure. Limbs that had type II and
type III anatomical failures were found to be more prone to varicose vein recurrence.
Conclusions: Endovascular radiofrequency obliteration of saphenous vein reflux exhibits enduring efficacy. Adequate
pullback speed during the procedure should be emphasized to ensure the proper thermal dose delivery. A whole treatment
strategy to address hemodynamically significant tributaries and perforators can further improve treatment outcomes.
Body mass index is a risk factor for anatomical failure, indicating the impact of hemodynamic factors on disease
progression and recurrence. ( J Vasc Surg 2005;42:502-9.)Great saphenous vein (GSV) reflux is an important
component of the pathophysiology of primary venous in-
sufficiency and is customarily treated with surgical stripping
of the GSV from the groin to just below the knee. For
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doi:10.1016/j.jvs.2005.05.007nearly a century, vein stripping, with minimal modifica-
tions, has remained the standard of care for symptomatic
varicose veins despite the observation of recurrence rates
ranging from 20% to 80%, depending on the definition of
recurrence.1,2
Endovenous radiofrequency obliteration (RFO), also
known as the Closurer procedure (VNUS Medical Tech-
nologies, Inc, San Jose, Calif), was introduced in Europe in
1998 and to theUnited States in 1999. The clinical benefits
of this technique have been demonstrated through three
separate randomized clinical studies comparing RFO with
conventional vein stripping.3-5 The short- and mid-term
treatment outcomes have been reported by several
groups.6-9 In this study, we report the 5-year follow-up
results of a multicenter registry. Factors related to treat-
ment failure and later varicose vein recurrence were also
analyzed.
MATERIALS AND METHODS
Data were collected in an ongoing multicenter, pro-
spective registry. This report includes the results from all
patients in the registry treated without concomitant high
ligation. Patients were treated before October 2004 at 34
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follow-up data.
Patients with superficial venous insufficiency confirmed
by duplex ultrasound scanning were considered as candi-
dates for RFO treatment. Saphenous vein incompetence
was diagnosed with saphenofemoral, saphenopopliteal, or
truncal vein reflux in response to manual compression and
release with patient standing or with Valsalva maneuver in a
15° reverse Trendelenburg position. Exclusions for saphe-
nous vein aneurysm and vein diameters 12 mm were
initially established as a conservative measure and were later
discontinued after reports of routinely successful treatment
in patients with these anatomical features.
Technical details of the RFO procedure have been
described elsewhere.9 In brief, vein access was achieved
through either percutaneous access or a small cut down. A
Closure catheter was advanced to the saphenofemoral junc-
tion (SFJ) or the saphenopopliteal junction (SPJ), and the
electrodes were placed distal to the SFJ or SPJ under
ultrasound guidance. Procedure evolution included the
gradual introduction of subcutaneous saline infiltration and
later perivenous tumescent infiltration. The treatment tem-
perature was set at 85°C. After starting radiofrequency
energy delivery and achieving treatment temperature for 15
seconds, the catheter was withdrawn at approximately 2 to
3 cm/min along the length of the vein while maintaining
the target temperature 3°C. Adjunctive procedures at the
time of treatment included phlebectomy and sclerotherapy
of visible varicose veins. Patients were advised to ambulate
and return to normal activities shortly after the procedure.
After the procedure, a duplex ultrasound examination
was routinely performed 1 week (preferably 72 hours)
to check for any evidence of thrombus extension from the
SFJ or SPJ into the deep system and to document the
occlusion status of the treated veins. Further follow-up
ultrasound scans and physical examinations were per-
formed at 6 months, 1 year, and each year thereafter.
Reflux was defined as any evidence of reverse flow0.5
seconds in any treated vein segment or in the area of the SFJ
(or SPJ). As reported, RFO often started 1 to 2 cm below
the SFJ, and the most common duplex finding after the
treatment was a short patent terminal GSV segment con-
ducting prograde tributary flow through the SFJ.10 Vein
occlusion was defined as the absence of any blood flow 3 cm
inferior to the SFJ or SPJ along the length of treated vein
segments. Symptom severity and clinical assessment ac-
cording to CEAP clinical classification were recorded at
each visit.
Three types of failure mode were identified based on
duplex ultrasound examination results. To differentiate
these failures from actual clinical failure, failure identified
by the duplex ultrasound was referred to as anatomical
failure. Risk analysis was performed to determine any fac-
tors associated with anatomical failure. The clinical impli-
cation of anatomical failure was analyzed based on clinical
symptoms and signs as well as varicose vein recurrence.
Statistical analysis. Measurable values were expressed
as mean  standard deviation, and the Student’s t test wasused to determine the statistical significance. Ratios were
expressed as mean (95% confidence interval [CI]), and the
2 or Fisher’s test was used to determine statistical signifi-
cance. Considering that the data series included the early
experience and several procedural changes were incorpo-
rated during the study period that improved clinical out-
comes, survival analysis was not performed. Vein occlusion,
absence of reflux, and varicose vein recurrence were thus
analyzed at each follow-up time point.
Stepwise logistic regression analysis for analyzing di-
chotomous response data (eg, success or failure, present or
not present) while accommodating adjustments for one or
more explanatory variables (risk factors) was performed for
anatomical failure and varicose vein recurrence. Risk factors
considered in the anatomical failure analysis were gender,
age, body mass index (BMI), vein diameter, and catheter
pullback speed. For varicose vein recurrence, the three
types of anatomical failure mode were considered as risk
factors. The regression parameter () of a risk factor in the
logistic model was tested for significance at the level of 5%
usingWald 2method. The corresponding odds ratios (OR
 e) were calculated and the 95% confidence limits (Wald)
were presented in brackets. Statistical Analysis System
(SAS) software (SAS Institute, Cary, NC) was used for the
data analysis.
RESULTS
There were 1,006 patients (1,222 limbs) treated from
34 centers (see Appendix) consisting of 23 private practice
centers, 10 university hospitals, and 1 state hospital. The
average age was 47.4  12.1 years (range, 15 to 97 years)
with a BMI of 24.8  4.9, and 78.1% of the patients were
female. The CEAP clinical class distribution before the
treatment is listed in Table I. The most common symptoms
in the limbs were pain in 85.3%, fatigue in 78.6%, and
edema in 39.2%.
All of the veins treated had reflux 0.5 seconds before
the treatment documented by duplex ultrasound examina-
tion as described previously in theMethods section. Among
the veins treated, 89.1% were GSV limited to the thigh
segment (access at above the knee or just below the knee),
4.1% GSV from groin to ankle, 1.2% GSV limited to the
below-knee segment, 4.3% SSV, and 1.3% accessory saphe-
Table I. Maximum preoperative CEAP clinical class
distribution
CEAP clinical class % each CEAP
0 0.5%
1 2.5%
2 69.6%
3 10.1%
4 13.1%
5 1.2%
6 1.1%
Not recorded 1.9%nous veins. The mean diameter, measured with the patient
rtesy
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phlebectomy was performed in 52% of limbs and sclero-
therapy in 11% of limbs at the time of RFO treatment.
Vein occlusion and hemodynamic outcomes. Limbs
at risk and limbs available for follow-up at each time point
are summarized in Table II. Immediate vein occlusion was
achieved in 96.8% of limbs confirmed by duplex ultrasound
examination 1 week after the procedure. The vein occlu-
sion rate at 6 months, 1, 2, 3, 4, and 5 years was 89.2%,
87.1%, 88.2%, 83.5%, 84.9%, and 87.2%, respectively; and
the absence of reflux rate was 91.3%, 88.2%, 88.2% 88.0%
86.6%, and 83.8%, respectively, at each time point. A
duplex image taken at 5 years of an occluded GSV is shown
in Fig 1.
For those 30 limbs (3.2%) that did not achieve imme-
diate occlusion, subsequent intervention to the GSV was
done in three limbs, two with sclerotherapy and one with
high ligation. As of the last reported follow-up, 24 limbs
received no further GSV treatment, seven of the 24 had
spontaneous occlusion at a later time point, and another
three limbs had no further follow-up information.
Anatomical failure mode and risk factors. Over a
5-year follow-up on 1,222 limbs treated, duplex ultrasound
examination identified 185 limbs that had either one of the
following: flow in a segment of or the entire treated vein, or
developed groin reflux despite a completely occluded GSV
trunk. These findings were defined as anatomical failure.
The mode of anatomical failure can be categorized into
Fig 1. On the left, a duplex ultrasound image of the a
quency obliteration of the great saphenous vein (GSV).
Transverse views of patent tributaries (Trib) are seen. Th
Superficial epigastric vein; FE, femoral vein. (Images cou
Table II. Vein occlusion and hemodynamic outcomes
1 wk 6 mo
Limbs at risk 1,222 1,220
Limbs available for follow-up 985 518
Vein occlusion 96.8% 89.2%
Absence of reflux 96.6% 91.3%three types, illustrated in Fig 2:● Type I (nonocclusion) failure referred to veins that
failed to occlude initially and never occluded during
the follow-up. There were 23 limbs belonging to this
category, consisting of 12.4% (23/185) of all anatom-
ical failures. Among these 23 limbs, eight (34.8%) were
significantly narrowed, with no reflux irrespective of a
patent trunk.
● Type II failure (recanalization) referred to veins that
were initially occluded but recanalized, partly or com-
pletely, at a later time point. There were 129 limbs in
this category, accounting for 69.7% (129/185) of the
total anatomical failure. Among the 129 type II limbs,
44 (34.1%) exhibited no reflux. There was documen-
tation in 30 (23.3%) type II limbs that the recanaliza-
tion was directly related to either a refluxing tributary
or an incompetent thigh perforator.
● Type III failure (groin reflux) referred to the situation
in which the vein trunk was occluded, but reflux was
detected at the groin region, often involving an acces-
sory vein. There were 33 type III limbs, which made
up 17.8% (33/185) of the total anatomical failure.
Only 19 (10.3%) of 185 limbs received reintervention
to address the anatomical failure: 11 limbs with sclerother-
apy resulting in secondary occlusion in 9 limbs, 2 limbs with
RFO and veins closed, 1 vein stripping, 2 high ligations,
and 3 nonspecified.
Logistic regression analysis found that the two risk
ear the saphenofemoral junction 1 week after radiofre-
age on the right was recorded at the 5-year follow-up.
e no longer any discernible landmarks for the GSV, Epi,
of Olivier Pichot, MD)
yr 2 yr 3 yr 4 yr 5 yr
206 1,141 991 833 406
473 263 133 119 117
.1% 88.2% 83.5% 84.9% 87.2%
.2% 88.2% 88.0% 86.6% 83.8%rea n
The im
ere ar1
1,
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regressionmodel, adjusted for the normal pullback speed of
3 cm/min and BMI of 25 kg/m2, was as follows:
logit (p^)  1.5979  0.2464 	 (pullback speed
3)  0.0356 	 (BMI  25). The p^ indicates an esti-
mated probability of anatomical failure.
The estimated slope coefficients indicated that the
probability of anatomical failure increased by 1.28 times
(95% CI: 1.13, 1.45) for each unit (1 cm/min) increase
over 3 cm/min in pullback speed using a target treatment
temperature of 85°C; and the probability of anatomical
failure increased by 1.04 times (95% CI: 1.00, 1.07) for
each unit (1 kg/m2) increase over 25 kg/m2 in BMI.
When further identifying which risk factor was associ-
ated with which type of anatomical failure, it was found that
the pullback speed was a risk factor for only type I and type
Fig 2. The the types of anatomical failure are illustrated
(GSV) failure to completely occlude, with or without re
Type III, the treated GSV is occluded, but reflux is presen
CFV, Common femoral vein.
Fig 3. As a measure of symptom relief following treatm
recorded.II failure but not type III failure. The BMI, however, failedto show significance for any individual failure type, likely
because of the small sample size that resulted in insufficient
statistical power in each failure category.
It is important to point out that anatomical failure does
not necessarily result in clinical failure. As detailed below,
most patients experienced symptom relief after the proce-
dure and remained asymptomatic in spite of anatomical
failure.
Clinical symptoms and signs. Patient symptom im-
provement was observed as early as 1 week after the treat-
ment (Fig 3). The percentage of limbs exhibiting pain
decreased from 85.3% pretreatment to 29.9% by 1 week,
10.0% by 6 months, and 8.5% by 5 years after the RFO
treatment. Limb fatigue was improved from 78.6% of limbs
before RFO to 7.3% at 1 week and 3.9% at 6 months after
treatment. The percentage of limbs with edema reduced to
e panels (left to right). A, Type I, great saphenous vein
resent. B and C, Type II, partially recanalized GSV. D,
olving branches near the saphenofemoral junction (SFJ).
presence or absence of limb pain, fatigue or edema wasin th
flux p
t invent,7.5% at 1 week and 3.3% at 6 months after RFO compared
ccessf
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effect on patient symptom improvement persisted over 5
years.
Significant symptom improvement was also seen in
patients with anatomical failures. As shown in Fig 4, even in
the anatomical failure patients, 70% to 80% of limbs re-
mained asymptomatic up to 5 years after the treatment,
suggesting the clinical benefit of the procedure even in
patients with a treated limb judged as an anatomical failure.
When the percentage of asymptomatic patients at each
follow-up time point was compared, no statistical signifi-
cance was found among the type I, II, or III patients (2
test). The data from these patients with anatomical failure
were thus combined and compared with anatomically suc-
cessful patients. As expected, the percentage of asymptom-
atic limbs was slightly lower in the anatomical failure group
compared with the anatomical success group (Fig 4).
CEAP clinical classification improvement is illustrated
in Fig 5. Before treatment, 92.8% of limbs were CEAP
clinical class 2 to 4. One week after the procedure, 66.2% of
limbs were CEAP clinical class 0 to 1. The percentage
increased to 77.0% by 6months, maintained stable through
3 years, and showed a slight decrease at 4 and 5 years.
Overall varicose vein recurrence rates at 6 months, 1, 2,
3, 4, and 5 years were 7.7% (40/518), 13.1% (62/473),
14.8% (39/263), 14.3% (19/133), 22.7% (27/119), and
27.4% (32/117), respectively.When the impact of anatom-
ical failure on varicose vein recurrence was examined, it was
found that type II (P  .0001) and type III (P  .0009)
failures were risk factors for varicose vein recurrence. The
Fig 4. Limbs that were asymptomatic at each time po
groups: those for which treatment was categorized as suodds ratio for varicose vein recurrence was 3.8 (95% CI:2.5, 5.9) when there was a type II failure and 4.0 (95% CI:
1.8, 9.2) where there was a type III failure.
Complications. Complications associated with the
RFO procedure were reported and discussed in detail pre-
viously.7-9,11 The first published report on RFO recom-
mended a follow-up duplex evaluation72 hours, and this
has been standard follow-up protocol since 1999.11 Early
complications in this series included 0.9% deep venous
thrombosis (DVT) or clot extension into the common
femoral vein, 1.2% skin burn, 2.9% clinical phlebitis, and
0.2% infection at the vein access site. No limbs exhibited
lymphedema at any follow-up visits. A pulmonary embo-
lism developed in one of the patients withDVT, as reported
elsewhere.9,11 All thrombotic episodes were successfully
treated with anticoagulation therapy or thrombectomy (n
 1). Skin burn complications occurred primarily before
the implementation of tumescent infiltration to protect the
skin.
Paresthesia, often presenting as focal hypoesthesia, was
observed in 121 (12.3%) of 985 limbs at the initial 1-week
follow-up. The incidence decreased to 7.3% by 6 months
and was 2.6% at 5 years. For GSV below-knee treatment,
the paresthesia rate was 13.3%, 11.6%, and 7.7% at 1 week,
6 months, and 5 years, suggesting a trend towards a higher
paresthesia rate with below-knee GSV treatment. The par-
esthesia rate associated with SSV treatment was 8.9% and
9.5% at 1 week and 6 months.
DISCUSSION
Vein stripping and high ligation has been the standard
r limb pain, fatigue, or edema were separated into two
ul and those categorized as anatomical failure.int foof care for superficial venous insufficiency for many de-
g wi
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often performed by using varicose vein recurrence as the
primary end point. Only recently, because of the wide
availability of duplex ultrasound scanning, has the signifi-
cance of recurrent reflux been recognized. The prevalence
of recurrent reflux increases over time, with a 28.8% inci-
dence at 5 years12 and 60% at a mean follow-up of 34
years.13
Themechanism responsible for recurrence has been the
topic of a long-standing discussion. Recent published stud-
ies have provided sufficient evidence supporting neovascu-
larization as one of the major mechanisms for SFJ recur-
rence.13-19 In our study, 83.8% of GSVs were free from
reflux 5 years after RFO, and ultrasound evidence of neo-
vascularization was detected in only two limbs through the
follow-up period, suggesting a significant advantage of this
procedure over conventional vein stripping. It is speculated
that avoiding a groin incision and preservation of physio-
logic flow from junctional tributaries draining the abdom-
inal and pudendal areas diminish angiogenic stimuli and
thus reduce neovascularization.20
Anatomical failure after an RFO procedure can be
categorized into three types. Type I failure (nonocclusion)
refers to the situation when a vein fails to occlude and is
often due to less than optimal procedural techniques, such
as a too fast pullback speed that results in an insufficient
thermal dose. Type I failures can be reduced by following a
recommended and standardized procedural methodology.
It has also been observed that in a very small percentage of
patients, veins were nonresponsive to thermal obliteration,
even after repeated treatment attempts. It has been specu-
lated that the collagen structure might be different or that
inflammatory swelling after vein wall heating is attenuated
in these patients, but there is no evidence as yet to prove
these hypotheses. Despite this, frequently the open vessel
Fig 5. Percentages of limbs presentinhas shrunk in diameter, often without reflux.Recanalization (type II failure), 23.3% of which were
associated with either tributary or perforator incompe-
tence, accounted for 69.7% of the total anatomical failures.
The significance of tributary or thigh perforator incompe-
tence and its relationship to the durability of endovenous
obliteration has not been given much attention in the past.
Results from this study suggest that proactively addressing
tributary and perforator incompetence may further im-
prove long-term RFO treatment outcomes. A thorough
preoperative ultrasound study and diligent ultrasound
follow-up to identify refluxing tributaries and thigh perfo-
rators can lead to a carefully designed treatment plan to
address all refluxing sources, with either endovenous abla-
tion or surgical ligation.
In addition to type I and II failure, groin reflux devel-
oped in 33 limbs (17.8% of total failures) despite complete
occlusion of the GSV trunk (type III). The reflux often
involved an accessory saphenous vein associated with or
“feeding” varicosities. This type of failure likely reflects
disease progression associated with persistent hypertension
of the venous system, but a contributing factor may also be
an undiagnosed accessory vein incompetence that existed at
the time of GSV treatment.
Risk analysis revealed that the pullback speed was a risk
factor for type I and II failures. It is understandable that the
thermal dose delivered at a specific vein segment is related
to both the treatment temperature and the time, the latter
being a function of pullback speed. A certain level of
thermal dose is required to efficiently occlude the vein. An
insufficient thermal dose may result in short-term vein
occlusion, probably through formation of thrombosis in
the treated segment. However, the thrombotic occlusion is
subject to recanalization (type II), particularly when the
segment is associated with incompetent tributaries or per-
th CEAP clinical classification 0 to 1.forators.
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failure, although we were unable to further stratify whether
it was associated with all the types or only a specific type
because of small sample size in the failure group. Neverthe-
less, it is reasonable to suggest that preventive measures,
such as compression, should be provided after the treat-
ment to patients with a higher BMI. The mechanism by
which a high BMI results in anatomical failure remains
unclear. However, patients with high BMI values tend to
pose more procedural challenges such as inadequate com-
pression during RFO and incomplete removal of varicose
veins that result in incomplete relief of venous hyperten-
sion.21
It is important to note that anatomical failure does not
necessarily result in clinical recurrence. Most patients expe-
rienced clinical improvement, and 70% to 80% were asymp-
tomatic, irrespective of anatomical failure, during the
5-year follow-up period. This suggests that the anatomical
failure may not be significant enough to cause pressure-
related symptoms.
On the other hand, type II and type III failures were
risk factors for varicose vein recurrence. Type II failure
patients were 3.8 times and type III 4.0 times as likely to
develop varicose vein recurrence compared with anatomical
success patients. Type I failure did not reach statistical
significance in this analysis. One possible explanation is that
fewer of these patients had longer than 3 years follow-up,
may have been treated by other methods, or were lost to
follow-up, and therefore, the impact of early failure on
varicose vein recurrence may not be identified.
Surveillance monitoring, early recognition of anatomi-
cal failure, and taking further corrective action that may
include RFO retreatment21 may prevent some of the vari-
cose vein recurrence. However, it should be recognized
that the disease progression is likely to play a major role in
type III failure and may also account for some of the type II
failure. This may contribute to the increase in varicose vein
recurrence at 4 and 5 years.
In addition to theGSV, RFOhas also been used to treat
SSV and accessory saphenous vein incompetence in clinical
practice. In this series, 4.3% veins treated were SSV and
1.3% were accessory saphenous veins. Although there were
not enough samples and follow-up to demonstrate their
long-term efficacy, one would not expect a dramatic differ-
ence between them and the GSV treatment. In this series,
no serious adverse event such as motor nerve damage was
reported with SSV treatment. The paresthesia rate in the
SSV group was 8.9% at 1 week and 9.5% at 6 months,
similar to that with the GSV treatment. The technical
aspects of perivenous tumescent infiltration, catheter tip
placement, and patient response monitoring during the
procedure demand special attention with the SSV treat-
ment to protect the sural nerve and other surrounding
nerves. When these elements were applied to SSV proce-
dures, the paresthesia incidence dropped to as low as 0.3%
(1/30) at one center.Application of tumescence during endovenous obliter-
ation is one of the most important procedural advance-
ments during the last several years. It has been shown
previously that tumescent infiltration can significantly de-
crease procedure complications.22 With perivenous tumes-
cence, RFO can be used effectively to treat larger diameter
veins (12 mm in diameter) without compromise of treat-
ment efficacy.22 In the current series, the largest vein that
was treated effectively was 24 mm in diameter.
CONCLUSION
Five-year follow-up on patients treated with en-
dovenous radiofrequency obliteration has demonstrated
that vein occlusion and clinical improvement are durable.
Risk analysis in this international multicenter registry iden-
tified catheter pullback speed and body mass index as the
two risk factors associated with RFO anatomical failures.
Although historical data on traditional vein stripping can
only serve as a reference and not a direct comparison, the
clinical recurrence and neovascularization appear to be low
in RFO patients. The data from this report and from
randomized trials of RFO versus vein stripping clearly
indicate that RFO provides long-term efficacy and is better
for the patients. The combination of positive level-one
evidence and 5-year confirmation of procedure efficacy
with RFO indicates that it has been evaluated extensively
enough to be considered at least a comparable standard of
care alongside traditional surgery.
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Endovenous treatment to obliterate the saphenous vein may
be performed by several techniques, including radiofrequency
ablation, laser treatment, or foam sclerotherapy. In this study, Dr
Merchant reports the data from an ongoing multicenter prospec-
tive registry of radiofrequency ablation treatment. Clinical and
duplex follow-up was performed within 1 week, at 6 months, at 1
year, and yearly thereafter. A total of 1006 patients and 1222 limbs
were treated; most involved the greater saphenous vein above the
knee. Vein occlusion rates ranged from 83.5% to 88.2%. Clinical
symptom improvement was noted in 70% to 80% of limbs with
anatomic failure and in 85% to 94% of limbs with anatomic success.
There is no question that endovenous saphenous vein ablation
is here to stay. The stage was set for such a procedure by the
determination that patients had better results with varicose vein
surgery if the saphenous vein was removed along with saphe-
nofemoral ligation, rather than with ligation alone.1 Saphenous
vein ablation, even in the presence of deep venous insufficiency,
can improve the manifestations of chronic venous insufficiency.2
As indicated by the authors, three randomized trials have estab-
lished the superiority of endovenous radiofrequency ablation to
saphenous vein surgery. The importance of the current study is to
show the durability of endovenous radiofrequency closure over 5
years. Two disappointing aspects of the report include the fact thatand that body mass index correlated with anatomic failure. It is
exactly in this type of patient that endovenous ablation is most
appealing as opposed to operative ligation and stripping. Addition-
ally, before radiofrequency ablation is embraced as the best
method for saphenous vein ablation, more comparisons to laser
and foam sclerotherapy, techniques that have shown excellent
results, should be performed.3,4 Nonetheless, this study is an
important contribution to our understanding of the durability and
efficacy of this new modality for the treatment of saphenous vein
reflux.
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